June 30, 2022The Lancet Regional Health - Europe326 citationsOpen Access
Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
The study was sponsored by AstraZeneca.